PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
26.95%
R&D growth while AVXL reduces spending. John Neff would investigate strategic advantage.
24.63%
G&A growth above 1.5x AVXL's 8.79%. Michael Burry would check for operational inefficiency.
No Data
No Data available this quarter, please select a different quarter.
3.65%
Other expenses change of 3.65% while AVXL maintains costs. Bruce Berkowitz would investigate efficiency.
26.14%
Operating expenses growth while AVXL reduces costs. John Neff would investigate differences.
26.14%
Total costs growth while AVXL reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
3.65%
D&A growth while AVXL reduces D&A. John Neff would investigate differences.
-26.20%
EBITDA decline while AVXL shows 5.03% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-26.14%
Operating income decline while AVXL shows 4.03% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-1.70%
Other expenses reduction while AVXL shows 17056.63% growth. Joel Greenblatt would examine advantage.
-26.43%
Pre-tax income decline while AVXL shows 39.69% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-26.43%
Net income decline while AVXL shows 40.04% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-26.52%
EPS decline while AVXL shows 42.73% growth. Joel Greenblatt would examine position.
-26.52%
Diluted EPS decline while AVXL shows 42.73% growth. Joel Greenblatt would examine position.
0.09%
Share count reduction exceeding 1.5x AVXL's 1.50%. David Dodd would verify capital allocation.
0.09%
Diluted share reduction exceeding 1.5x AVXL's 1.50%. David Dodd would verify capital allocation.